fluorobenzenes has been researched along with Cardiovascular Stroke in 75 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.33) | 18.2507 |
| 2000's | 18 (24.00) | 29.6817 |
| 2010's | 56 (74.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asai, K; Ibuki, C; Inami, S; Inui, K; Kamiya, M; Kawanaka, H; Kikuchi, A; Kusama, Y; Miyachi, H; Mizuno, K; Munakata, K; Ohba, T; Seino, Y; Takagi, G; Takahashi, Y; Takano, H; Tanabe, J; Tanaka, K; Yamamoto, E; Yasutake, M | 1 |
| Aggarwal, RK; Showkathali, R | 1 |
| Balu, S; Montouchet, C; Ruff, L | 1 |
| Biondi-Zoccai, G; Calcagno, S; Canali, E; Conti, G; Fedele, F; Lucisano, L; Mancone, M; Pennacchi, M; Sardella, G; Stio, RE | 1 |
| Ballantyne, CM; Barter, PJ; Chapman, MJ; Erbel, R; Kataoka, Y; Libby, P; Nicholls, SJ; Nissen, SE; Puri, R; Raichlen, JS; Shao, M; Uno, K | 1 |
| Aydogdu, S; Canpolat, U; Cay, S; Durmaz, T | 1 |
| Glynn, RJ; Mora, S; Ridker, PM | 1 |
| Aksakal, E; Ekinci, M; Işik, T; Kaya, A; Kaya, Y; Kurt, M; Sevimli, S; Tanboğa, IH; Topçu, S | 1 |
| Askevold, ET; Aukrust, P; Gravning, J; Gullestad, L; Kjekshus, J; McMurray, JJ; Nymo, SH; Ueland, T; Wikstrand, J | 1 |
| Lucisano, L; Sardella, G | 1 |
| Bae, JH; Choi, D; Hong, MK; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, S; Lim, DS; Shin, DH; Won, H | 1 |
| Dicker, D; Elis, A; Gevrielov-Yusim, N; Goldenberg, I; Klempfner, R; Kopel, E; Matetzky, S; Pereg, D | 1 |
| Böhm, M; Cleland, JG; Gullestad, L; Jhund, PS; Kjekshus, J; McMurray, JJ; Perez, AC; Pocock, SJ; Rogers, JK; van Veldhuisen, DJ; Wedel, H; Wikstrand, J | 1 |
| Chitose, T; Hokamaki, J; Ogawa, H; Sakamoto, K; Shimomura, H; Shiraishi, S; Sugiyama, S; Tsunoda, R; Yamashita, T; Yamashita, Y | 1 |
| Jia, D; Li, W; Lv, Y; Shu, W; Wu, N | 1 |
| Berdan, LG; Bessac, L; Bhatt, DL; Bittner, V; Diaz, R; Goodman, SG; Hanotin, C; Harrington, RA; Jukema, JW; Mahaffey, KW; Moryusef, A; Pordy, R; Roe, MT; Rorick, T; Sasiela, WJ; Schwartz, GG; Shirodaria, C; Steg, PG; Szarek, M; Tamby, JF; Tricoci, P; White, H; Zeiher, A | 1 |
| Li, L; Tian, JH; Yang, K; Zhang, P | 1 |
| Guo, M; Huang, D; Li, JB; Li, S; Wang, FB; Wei, M; Yan, ML; Yu, T | 1 |
| Dubrovins'ka, TV; Skrypnyk, IM | 1 |
| Qu, Y; Xia, J; Xu, D; Yin, C | 1 |
| Phongtuntakul, B; Tungsubutra, W | 1 |
| Colivicchi, F | 1 |
| Erdmann, E; Hoppe, UC | 1 |
| Danielson, E; Fonseca, FA; Genest, J; Glynn, RJ; Gotto, AM; Kastelein, JJ; Koenig, W; Libby, P; Lorenzatti, AJ; MacFadyen, JG; Nordestgaard, BG; Ridker, PM; Shepherd, J; Willerson, JT | 1 |
| Dobson, R | 1 |
| Basso, N; Berg, G; Buchholz, B; Carrión, CL; D'Annunzio, V; Donato, M; Erni, L; Gelpi, RJ; Miksztowicz, V; Schreier, L; Wikinski, R | 1 |
| Badimon, L; Casaní, L; Duran, X; Juan-Babot, O; Peña, E; Vilahur, G | 1 |
| Kones, R | 1 |
| Bailey, KM; Balmforth, AJ; Barth, JH; Copeland, J; Efthymiou, M; Farrin, AJ; Flather, MD; Hall, AS; Jackson, BM; McCormack, T; Nixon, J; Romaine, SP; Whitehead, A | 1 |
| Fonseca, FA; Izar, MC | 1 |
| Fonseca, FA; Genest, J; Glynn, RJ; Gotto, AM; Kastelein, JJ; Koenig, W; Libby, P; Lorenzatti, AJ; MacFadyen, JG; Nordestgaard, BG; Ridker, PM; Shepherd, J; Willerson, JT | 1 |
| Bailey, KM; Balmforth, AJ; Barth, JH; Copeland, J; Efthymiou, M; Farrin, AJ; Flather, MD; Hall, AS; Jackson, BM; McCormack, T; Nixon, J; Romaine, SP; Samani, NJ; Whitehead, A | 1 |
| Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Durmaz, T; Sen, N | 1 |
| Chen, Y; Cheng, X; Ding, Y; Fu, M; Liao, M; Liao, Y; Tang, T; Xiao, H; Xie, J; Xu, Y; Yao, R; Yu, X; Zhao, G | 1 |
| Boekholdt, SM; Genest, J; Glynn, RJ; Gotto, AM; Kastelein, JJ; Libby, P; MacFadyen, JG; Mora, S; Nordestgaard, BG; Ridker, PM | 1 |
| Bailey, KM; Balmforth, AJ; Barth, JH; Copeland, J; Efthymiou, M; Farrin, AJ; Flather, MD; Hall, AS; Jackson, BM; McCormack, T; Nixon, J; Romaine, SP; Whitehead, A; Worthy, G | 1 |
| Lupattelli, G; Mannarino, E; Roscini, AR; Siepi, D | 1 |
| Neft, M | 1 |
| Melfi, R; Nusca, A; Patti, G; Sciascio, GD | 1 |
| Koenig, W; Ridker, PM | 1 |
| Schunn, H | 1 |
| Drexel, H; Saely, CH; Vonbank, A | 1 |
| Antonsen, L; Egede, R; Hansen, HS; Hansen, KN; Jensen, LO; Junker, A; Thayssen, P | 1 |
| Aiello, VD; Casella Filho, A; Chagas, AC; da Luz, PL; Dourado, PM; Galvao, TF; Landim, MB; Mathias, W; Tsutsui, JM | 1 |
| Algra, A; de Wit, GA; Greving, JP; Visseren, FL | 1 |
| Qian, HY; Tang, YD; Wang, H; Xu, H; Yang, YJ; Zhang, Q | 1 |
| Ballantyne, CM; Davidson, MH; Friedewald, VE; Gotto, AM; Ridker, PM; Roberts, WC | 1 |
| Fellström, BC; Holdaas, H; Holme, I; Jardine, AG; Norby, GE; Schmieder, RE; Zannad, F | 1 |
| Krane, V; Wanner, C | 1 |
| Liao, ZJ; Lin, ZP; Liu, Q; Shu, PC; Wang, XQ | 1 |
| Akçalı, Z; Borlu, F; Namal, E; Oztekin, E; Sener, N; Ulaş, T | 1 |
| Serebruany, VL | 1 |
| Schaefer, JR | 1 |
| Adourian, A; Aukrust, P; Böhm, M; Cleland, JG; Gullestad, L; Hulthe, J; Kjekshus, J; Komajda, M; McMurray, JJ; Muntendam, P; Nymo, SH; Ueland, T; van Veldhuisen, DJ; Wikstrand, J | 1 |
| Calcagno, S; Canali, E; Conti, G; De Carlo, C; Di Roma, A; Donahue, M; Fedele, F; Lucisano, L; Mancone, M; Sardella, G | 1 |
| Alperin, P; Gandhi, S; Hsia, J; Peskin, B; Schuetz, CA; van Herick, A | 1 |
| Abo-Gresha, NM; Zaitone, SA | 1 |
| Gao, Y; Jia, ZM; Qi, GX; Ren, LN; Sun, YJ; Zhang, ZH | 1 |
| Egede, R; Hansen, HS; Hansen, KN; Jensen, LO; Junker, A; Thayssen, P | 1 |
| Ge, J; Hu, X; Huang, Z; Jia, J; Sun, A; Xie, X; Yao, R | 1 |
| Aukrust, P; Gullestad, L; Hulthe, J; Kjekshus, J; McMurray, JJ; Muntendam, P; Nymo, SH; Ueland, T; Wikstrand, J | 1 |
| Kanorskiĭ, SG; Shevelev, VI | 1 |
| Dai, H; Ge, Z; Hou, F; Lin, X; Ma, Y; Ren, Y; Tan, K; Wang, S; Wang, Y; Wang, Z; Xing, M; Yu, Z; Zhang, J | 1 |
| Cao, F; Cui, M; Gao, X; Han, Y; Jia, H; Li, C; Li, S; Narsinh, K; Qin, X; Sun, D; Wang, H; Zhang, Z | 1 |
| Ridker, PM | 1 |
| Bloch, KD; Gannon, J; Lee, RT; Lian, Q; MacGillivray, C; Nasseri, BA; Picard, MH; Scherrer-Crosbie, M; Weinberg, EO | 1 |
| Bauersachs, J; Eigenthaler, M; Ertl, G; Firnschild, A; Fraccarollo, D; Frantz, S; Schäfer, A; Tas, P | 1 |
| Scalia, R | 1 |
| Clark, AL; Cleland, JG; Coletta, AP; Nikitin, NP | 1 |
| Bulhak, A; Hedin, U; Pernow, J; Roy, J; Sjöquist, PO | 1 |
| Cannon, CP; Kumar, A | 1 |
| Loscalzo, J; Pitt, B; Raichlen, JS; Ycas, J | 1 |
| Fischer, G; Grohs, JG; Raberger, G | 1 |
10 review(s) available for fluorobenzenes and Cardiovascular Stroke
| Article | Year |
|---|---|
Rosuvastatin calcium in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Animals; Cholesterol, LDL; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Practice Guidelines as Topic; Pyrimidines; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides | 2013 |
Statins for primary prevention of venous thromboembolism.
Topics: Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Stroke; Sulfonamides; Venous Thromboembolism; Venous Thrombosis | 2014 |
[Cardiology 2008].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Aortic Valve Stenosis; Cardiac Catheterization; Cardiovascular Diseases; Drug Therapy, Combination; Electrocardiography; Fluorobenzenes; Heart Failure; Heart Valve Prosthesis Implantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Myocardial Infarction; Platelet Aggregation Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides | 2008 |
The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
Topics: Angina, Unstable; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Female; Fluorobenzenes; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome | 2009 |
Change in serum lipids after acute coronary syndromes: secondary analysis of SPACE ROCKET study data and a comparative literature review.
Topics: Cholesterol; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Multicenter Studies as Topic; Myocardial Infarction; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2010 |
Statin loading before percutaneous coronary intervention: proposed mechanisms and applications.
Topics: Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Atorvastatin; Biomarkers, Pharmacological; Confidence Intervals; Endothelium, Vascular; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Inflammation; Kidney Diseases; Multivariate Analysis; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2010 |
[HDL level or HDL function as the primary target in preventive cardiology].
Topics: Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Membrane Transport Proteins; Myocardial Infarction; Niacin; Pyrimidines; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Reference Values; Rosuvastatin Calcium; Scavenger Receptors, Class B; Sulfonamides; Survival Rate; Up-Regulation | 2012 |
High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention.
Topics: Aged; C-Reactive Protein; Female; Fluorobenzenes; Humans; Male; Metabolic Syndrome; Middle Aged; Myocardial Infarction; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sensitivity and Specificity; Sulfonamides | 2003 |
Statins and the response to myocardial injury.
Topics: Animals; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2005 |
Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Coronary Angiography; Coronary Disease; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pravastatin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Ultrasonography, Interventional | 2007 |
29 trial(s) available for fluorobenzenes and Cardiovascular Stroke
| Article | Year |
|---|---|
Usefulness of rosuvastatin to prevent periprocedural myocardial injury in patients undergoing elective coronary intervention.
Topics: Acyl Coenzyme A; Aged; Angioplasty, Balloon, Coronary; Dose-Response Relationship, Drug; Elective Surgical Procedures; Female; Fluorobenzenes; Heart Injuries; Humans; Japan; Male; Middle Aged; Myocardial Infarction; Perioperative Care; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2013 |
Comparison of high reloading ROsuvastatin and Atorvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of MyocArdial periprocedural necrosis. The ROMA II trial.
Topics: Aged; Angina, Stable; Atorvastatin; Elective Surgical Procedures; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Necrosis; Percutaneous Coronary Intervention; Postoperative Complications; Preoperative Care; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2013 |
Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy.
Topics: Angina, Unstable; Atorvastatin; Cholesterol, LDL; Coronary Artery Disease; Female; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Plaque, Atherosclerotic; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome; Ultrasonography, Interventional | 2013 |
High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy.
Topics: Aged; Angina, Unstable; Apolipoprotein A-I; Asymptomatic Diseases; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Endpoint Determination; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Nuclear Magnetic Resonance, Biomolecular; Particle Size; Proportional Hazards Models; Pyrimidines; Risk; Rosuvastatin Calcium; Single-Blind Method; Stroke; Sulfonamides; Triglycerides | 2013 |
Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial).
Topics: Atorvastatin; Contrast Media; Coronary Angiography; Dose-Response Relationship, Drug; Electrocardiography; Female; Fluorobenzenes; Follow-Up Studies; Glomerular Filtration Rate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Kidney; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Turkey | 2013 |
Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trial.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Chronic Disease; Female; Fluorobenzenes; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Predictive Value of Tests; Prognosis; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sensitivity and Specificity; Stroke; Sulfonamides; Survival Rate; Troponin T | 2014 |
Efficacy of early intensive rosuvastatin therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (ROSEMARY Study).
Topics: Anticoagulants; Combined Modality Therapy; Double-Blind Method; Drug-Eluting Stents; Electrocardiography; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Placebos; Prospective Studies; Pyrimidines; Republic of Korea; Rosuvastatin Calcium; Secondary Prevention; Sulfonamides; Treatment Outcome | 2014 |
[Optimization of long-term hypolipidemia treatment of patients with myocardial infarction in combination with non-alcoholic steatohepatitis].
Topics: Atorvastatin; Bilirubin; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipids; Liver; Middle Aged; Myocardial Infarction; Non-alcoholic Fatty Liver Disease; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Transaminases; Triglycerides; Ursodeoxycholic Acid | 2014 |
Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure).
Topics: Aged; Chronic Disease; Epidemiologic Methods; Female; Fluorobenzenes; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Ischemia; Pyrimidines; Recurrence; Rosuvastatin Calcium; Sulfonamides | 2014 |
Effect of a hydrophilic and a hydrophobic statin on cardiac salvage after ST-elevated acute myocardial infarction - a pilot study.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Echocardiography; Fatty Acids; Female; Fluorobenzenes; Heart; Heptanoic Acids; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iodobenzenes; Male; Middle Aged; Myocardial Infarction; Myocardium; Natriuretic Peptide, Brain; Pilot Projects; Prospective Studies; Pyrimidines; Pyrroles; Radionuclide Imaging; Rosuvastatin Calcium; Sulfonamides; Thallium; Tomography, Emission-Computed, Single-Photon; Ubiquinone | 2014 |
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.
Topics: Acute Coronary Syndrome; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Fluorobenzenes; Heptanoic Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Myocardial Infarction; Proprotein Convertase 9; Proprotein Convertases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Serine Endopeptidases; Stroke; Sulfonamides; Treatment Outcome | 2014 |
Preoperative rosuvastatin protects patients with coronary artery disease undergoing noncardiac surgery.
Topics: Aged; Coronary Artery Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Postoperative Complications; Preoperative Care; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2015 |
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Topics: Aged; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Double-Blind Method; Female; Fluorobenzenes; Follow-Up Studies; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Muscular Diseases; Myocardial Infarction; Proportional Hazards Models; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides | 2008 |
A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial.
Topics: Aged; Biomarkers; Cholesterol; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Practice Guidelines as Topic; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; United Kingdom | 2009 |
Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention
Topics: Age Factors; Body Mass Index; C-Reactive Protein; Cholesterol, LDL; Double-Blind Method; Endpoint Determination; Female; Fluorobenzenes; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metabolic Syndrome; Myocardial Infarction; Myocardial Revascularization; Primary Prevention; Pyrimidines; Racial Groups; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides | 2009 |
Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study.
Topics: Aged; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cholesterol, LDL; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Fluorobenzenes; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Myocardial Infarction; Neoplasm Proteins; Odds Ratio; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pyrimidines; Regression Analysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Prevention of peri-procedural myocardial injury using a single high loading dose of rosuvastatin.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Biomarkers; Creatine Kinase, MB Form; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Intraoperative Complications; Male; Middle Aged; Myocardial Infarction; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome; Troponin I | 2010 |
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
Topics: Adult; Aged; Angina, Unstable; Angioplasty; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Primary Prevention; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome | 2010 |
Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authorities.
Topics: Aged; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Primary Prevention; Pyrimidines; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides | 2011 |
Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high risk patients.
Topics: Aged; Brachial Artery; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Triglycerides; Ultrasonography; Vasodilation | 2012 |
Rosuvastatin in diabetic hemodialysis patients.
Topics: Aged; Aged, 80 and over; C-Reactive Protein; Diabetes Complications; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Myocardial Infarction; Pyrimidines; Renal Dialysis; Rosuvastatin Calcium; Sulfonamides | 2011 |
[Rosuvastatin improves myocardial function and arteriosclerosis plaque in patients with ST-segment elevation after acute myocardial infarction and percutaneous coronary intervention].
Topics: Aged; Angioplasty, Balloon, Coronary; Coronary Artery Disease; Electrocardiography; Female; Fluorobenzenes; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
[Effects of different statins, ezetimibe/simvastatin combination on hsCRP levels in unstable angina pectoris and non-ST elevation myocardial infarction patients: a randomized trial].
Topics: Angina, Unstable; Atorvastatin; Azetidines; C-Reactive Protein; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Single-Blind Method; Sulfonamides; Treatment Outcome | 2011 |
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
Topics: Aged; Biomarkers; C-Reactive Protein; Female; Fluorobenzenes; Galectin 3; Heart Failure, Systolic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Lipid Metabolism; Male; Myocardial Infarction; Natriuretic Peptide, Brain; Peptide Fragments; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome | 2012 |
Rosuvastatin pretreatment in patients undergoing elective PCI to reduce the incidence of myocardial periprocedural necrosis: the ROMA trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Cardiac Catheterization; Cardiotonic Agents; Coronary Angiography; Coronary Stenosis; Drug Administration Schedule; Female; Fluorobenzenes; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Necrosis; Percutaneous Coronary Intervention; Premedication; Prospective Studies; Pulse Therapy, Drug; Pyrimidines; Risk Assessment; Rosuvastatin Calcium; Sulfonamides; Survival Rate; Treatment Outcome | 2013 |
Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in female patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; C-Reactive Protein; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-1; Interleukin-6; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Tumor Necrosis Factor-alpha | 2012 |
Influence of high-dose lipid lowering treatment compared to low-dose lipid lowering treatment on plaque composition assessed by intravascular ultrasound virtual histology in patients with ST-segment elevation acute myocardial infarction: the VIRHISTAMI tr
Topics: Aged; Cholesterol, LDL; Electrocardiography; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Necrosis; Plaque, Atherosclerotic; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ultrasonography, Interventional | 2013 |
The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA).
Topics: Aged; Aged, 80 and over; Biomarkers; Female; Fluorobenzenes; Galectin 3; Heart Failure, Systolic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides | 2012 |
Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; C-Reactive Protein; Chemokine CCL2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Postoperative Complications; Preoperative Care; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2013 |
36 other study(ies) available for fluorobenzenes and Cardiovascular Stroke
| Article | Year |
|---|---|
Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
Topics: Adult; Atorvastatin; Costs and Cost Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Managed Care Programs; Models, Economic; Myocardial Infarction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; United States | 2013 |
High dose statins should be used in all patients undergoing percutaneous coronary intervention.
Topics: Elective Surgical Procedures; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Myocardial Infarction; Percutaneous Coronary Intervention; Postoperative Complications; Pyrimidines; Pyrroles; Sulfonamides | 2013 |
High dose statins should be used in all patients undergoing percutaneous coronary intervention.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Female; Fluorobenzenes; Humans; Intraoperative Complications; Male; Myocardial Infarction; Pyrimidines; Sulfonamides | 2014 |
Temporal trends in the use of high-dose potent statins following acute coronary syndrome in Israel.
Topics: Analysis of Variance; Angina, Unstable; Atorvastatin; Cohort Studies; Drug Prescriptions; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Israel; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Patient Discharge; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Treatment Outcome | 2014 |
Cardioprotective effects of low-dose combination therapy with rosuvastatin and fasudil in the isolated rat heart.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Apoptosis; Calcium Channel Blockers; Cardiotonic Agents; Drug Synergism; Enzyme Inhibitors; Fluorobenzenes; Heart; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Male; Myocardial Infarction; Myocardial Reperfusion Injury; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase Type III; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Ventricular Function, Left | 2014 |
Effect of combined treatment with rosuvastatin and protein kinase Cβ2 inhibitor on angiogenesis following myocardial infarction in diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Fluorobenzenes; Human Umbilical Vein Endothelial Cells; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Myocardial Infarction; Neovascularization, Physiologic; Nitric Oxide Synthase Type III; Phosphorylation; Protein Kinase C beta; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Rats; Rosuvastatin Calcium; Sulfonamides; Vascular Endothelial Growth Factor A | 2015 |
[Negative effects of termination statinotherapy in patients after acute coronary event with concominent non-alcoholic steatohepatitis].
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Non-alcoholic Fatty Liver Disease; Pyrimidines; Pyrroles; Recurrence; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2014 |
Achievement of LDL-cholesterol goal with statins after an st segment elevation myocardial infarction.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Cohort Studies; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Patient Discharge; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Thailand; Treatment Outcome | 2015 |
Statin reloading before noncardiac surgery: a simple, safe and effective approach for reducing the risk of perioperative myocardial infarction.
Topics: Coronary Artery Disease; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Postoperative Complications; Pyrimidines; Sulfonamides | 2015 |
Trial stopped early after rosuvastatin found to cut the risk of heart attack and stroke by 44% in healthy people.
Topics: Clinical Trials as Topic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides | 2008 |
Rosuvastatin given during reperfusion decreases infarct size and inhibits matrix metalloproteinase-2 activity in normocholesterolemic and hypercholesterolemic rabbits.
Topics: Animals; Doxycycline; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Myocardial Infarction; Myocardial Reperfusion; Myocardial Reperfusion Injury; Myocardium; Pyrimidines; Rabbits; Rosuvastatin Calcium; Sulfonamides | 2009 |
Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction.
Topics: Animals; bcl-2-Associated X Protein; Caspase 3; Disease Models, Animal; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Proto-Oncogene Proteins c-akt; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin for cardiovascular prevention: too many uncertainties.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Cardiovascular Diseases; Diabetes Mellitus; Double-Blind Method; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Pravastatin; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; Uncertainty | 2009 |
Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
Topics: Aged; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Stroke; Sulfonamides | 2009 |
Improved cardiac performance by rosuvastatin is associated with attenuations in both myocardial tumor necrosis factor-alpha and p38 MAP kinase activity in rats after myocardial infarction.
Topics: Animals; Blood Pressure; Blotting, Western; Cholesterol; Echocardiography; Fluorobenzenes; Heart; Heart Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Lipoproteins, LDL; Male; Myocardial Infarction; Myocardium; p38 Mitogen-Activated Protein Kinases; Pyrimidines; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Rosuvastatin Calcium; Sulfonamides; Triglycerides; Tumor Necrosis Factor-alpha; Ventricular Remodeling | 2010 |
Case report. Hyperlipoproteinaemia(a): which is the optimal therapy? A case report.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type I; Male; Middle Aged; Myocardial Infarction; Niacin; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Triglycerides | 2010 |
Interpreting and evaluating the details of the JUPITER study.
Topics: Clinical Trials as Topic; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides | 2010 |
[On the current debate on lowering LDL cholesterol with ezetimibe].
Topics: Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Financing, Personal; Fluorobenzenes; Germany; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Myocardial Infarction; National Health Programs; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides | 2010 |
HDL cholesterol and residual risk of first cardiovascular events.
Topics: Cholesterol, HDL; Coronary Artery Disease; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Infarction; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides | 2010 |
Rosuvastatin prevents myocardial necrosis in an experimental model of acute myocardial infarction.
Topics: Animals; Cholesterol, Dietary; Disease Models, Animal; Echocardiography; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Myocardial Infarction; Myocardium; Necrosis; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides | 2011 |
Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.
Topics: Aged; Cost-Benefit Analysis; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Markov Chains; Middle Aged; Myocardial Infarction; Pyrimidines; Quality-Adjusted Life Years; Rosuvastatin Calcium; Stroke; Sulfonamides; Treatment Outcome | 2011 |
Rosuvastatin treatment activates JAK-STAT pathway and increases efficacy of allogeneic mesenchymal stem cell transplantation in infarcted hearts.
Topics: Animals; Cell Differentiation; Cell Survival; Cell Tracking; Cells, Cultured; Disease Models, Animal; Enzyme Activation; Female; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Janus Kinase 2; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Myocardial Contraction; Myocardial Infarction; Myocardium; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Recovery of Function; Rosuvastatin Calcium; Signal Transduction; STAT3 Transcription Factor; Stroke Volume; Sulfonamides; Time Factors; Transplantation, Homologous; Tyrphostins; Ventricular Function, Left; Y Chromosome | 2011 |
The editor's roundtable: JUPITER follow-up.
Topics: C-Reactive Protein; Cholesterol, LDL; Clinical Trials as Topic; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Sunrise of statins after AURORA and 4D?
Topics: Diabetes Complications; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Myocardial Infarction; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2011 |
Extreme all-cause mortality in JUPITER requires reexamination of vital records.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Diabetic Angiopathies; Early Termination of Clinical Trials; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Myocardial Infarction; Primary Prevention; Pyrimidines; Randomized Controlled Trials as Topic; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides | 2011 |
Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model.
Topics: Age Factors; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Computer Simulation; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Models, Biological; Myocardial Infarction; Pyrimidines; Pyrroles; Risk Factors; Rosuvastatin Calcium; Sex Factors; Stroke; Sulfonamides | 2012 |
Rosuvastatin promotes angiogenesis and reverses isoproterenol-induced acute myocardial infarction in rats: role of iNOS and VEGF.
Topics: Acute Disease; Animals; Body Weight; Electrocardiography; Fluorobenzenes; Heart Ventricles; Isoproterenol; Male; Myocardial Infarction; Neovascularization, Physiologic; Nitric Oxide Synthase Type II; Organ Size; Pyrimidines; Rats; Rats, Wistar; Receptors, Complement 3b; Rosuvastatin Calcium; Sulfonamides; Survival Analysis; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2012 |
Rosuvastatin changes cytokine expressions in ischemic territory and preserves heart function after acute myocardial infarction in rats.
Topics: Animals; Cytokines; Fluorobenzenes; Gene Expression Regulation; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Ischemia; Pyrimidines; Random Allocation; Rats; Rats, Sprague-Dawley; Rosuvastatin Calcium; Sulfonamides; Ventricular Remodeling | 2013 |
[Antihypertensive therapy and dynamics of vascular wall rigidity in elderly patients with non-valvular atrial fibrillation].
Topics: Aged; Ankle Brachial Index; Anticholesteremic Agents; Antihypertensive Agents; Arterial Pressure; Arteries; Atrial Fibrillation; Combined Modality Therapy; Drug Monitoring; Female; Fluorobenzenes; Humans; Hypertension; Male; Myocardial Infarction; Perindopril; Pulse Wave Analysis; Pyrimidines; Rosuvastatin Calcium; Stroke; Sulfonamides; Tetrazoles; Treatment Outcome; Ultrasonography, Doppler, Duplex; Valine; Valsartan; Vascular Resistance | 2012 |
Rosuvastatin enhances the therapeutic efficacy of adipose-derived mesenchymal stem cells for myocardial infarction via PI3K/Akt and MEK/ERK pathways.
Topics: Adipocytes; Animals; Apoptosis; Cell Proliferation; Cell Survival; Combined Modality Therapy; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; MAP Kinase Signaling System; Mesenchymal Stem Cell Transplantation; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Myocardial Infarction; Myocytes, Cardiac; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Rosuvastatin Calcium; Signal Transduction; Sulfonamides; Treatment Outcome | 2013 |
Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion.
Topics: Animals; Coronary Disease; Fluorobenzenes; Heart Ventricles; Hematopoietic Stem Cell Mobilization; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ligation; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Pyrimidines; RNA, Messenger; Rosuvastatin Calcium; Stem Cells; Sulfonamides | 2005 |
Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability.
Topics: Animals; Cell Adhesion Molecules; Chronic Disease; Disease Models, Animal; Endothelium, Vascular; Fluorobenzenes; Heart Failure; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Microfilament Proteins; Myocardial Infarction; Nitric Oxide; Phosphoproteins; Phosphorylation; Platelet Activation; Pyrimidines; Rats; Reactive Oxygen Species; Rosuvastatin Calcium; Sulfonamides; Superoxides; Thrombosis; Vasoconstriction; Vasodilation; Ventricular Function, Left | 2005 |
Clinical trials update from the American College of Cardiology: Darbepoetin alfa, ASTEROID, UNIVERSE, paediatric carvedilol, UNLOAD and ICELAND.
Topics: Carbazoles; Carvedilol; Child; Cholesterol, LDL; Clinical Trials as Topic; Darbepoetin alfa; Diuretics; Erythropoietin; Fluorobenzenes; Heart Failure; Humans; Myocardial Infarction; Propanolamines; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Ultrafiltration | 2006 |
Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation.
Topics: Animals; Cardiovascular Agents; Cell Membrane; Cytosol; Disease Models, Animal; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Polyisoprenyl Phosphates; Protein Transport; Pyrimidines; Rats; Rats, Sprague-Dawley; rhoA GTP-Binding Protein; Rosuvastatin Calcium; Sulfonamides | 2007 |
Lipid levels after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Female; Fluorobenzenes; Heart Conduction System; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prognosis; Prospective Studies; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides; Time Factors; Triglycerides | 2008 |
Verification of a canine model of transient exercise induced myocardial dysfunction: antianginal effects of flestolol, an ultra short acting beta adrenoceptor antagonist.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Animals; Blood Pressure; Disease Models, Animal; Dogs; Fluorobenzenes; Heart Rate; Myocardial Infarction; Physical Exertion; Propanolamines; Time Factors | 1990 |